Pia Herbolsheimer

Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study

The Lancet Oncology · 2020 · 407 citations

Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study

Breast Cancer Research and Treatment · 2019 · 114 citations